7210 Wareham Drive, Tampa, FL 33647
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists […]
Zepbound Beats Wegovy for Weight Loss Read More »
Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic. The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The
GLP-1 Drugs Market Update Read More »
March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated
U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »
Jan. 11, 2024 The pandemic had significant effects on the way commercial weight loss companies operate, along with the explosive demand for GLP-1 obesity drugs such as Ozempic, Wegovy, and Mounjaro. Marketdata estimates that between Medifast, Weight Watchers, Jenny Craig, and Noom, at least 26,500 weight loss coaches have lost their jobs since 2020. Here’s
Ozempic Boom Is Hurting Weight Loss Coaches Read More »
Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In
Obesity Drug Sales Continue To Soar Read More »
August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after
More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »
January 27, 2023 Ozempic is a medication that’s designed to help manage insulin levels in people with type 2 diabetes. However, it’s recently gotten attention after some people spoke out on social media about using the drug for weight loss. Ozempic, which is a brand name for semaglutide, is currently on the Food and Drug Administration’s list of
“Ozempic Face” Side Effect Read More »